Spontaneous report was received on 08-AUG-2013 from a pharmacist regarding a 11 year old female patient, 
initials C-C, with thalassemia. On 06-AUG-2013, the patient initiated treatment with Campath .(alemtuzumab) 
solution for infusion at a dose of 7.2 mg once a day in preparation for a hematopoetic stem cell transplantation for 
thalasemia. The lot number of Campath was not provided. The patient received a dose of ceftriazone, Zantac and 
Benadryl as premedication for Campath infusion. On 07-AUG-2013, the patient had second of five planned doses 
of Campath. the patient developed complex atrial arrhythmia during infusion which was confirmed 
by cardiology as consistent with multifocal tachycardia or coarse atrial arrhythmia. On an unspecified date infarb 
NIP the patient was transferred to cardiac unit and initiated treatment with amiodarone drip. The treatment with 
Campath was temporarily discontinued. The patient had not yet recovered from the event of complex atrial 
arrhythmia. Concomitant medications included ceftriaxone, Benadryl (acrivastine) and Zentac (ranitidine 
hydrochloride). The intensity for the event was not provided. The reporter did not provide the relationship between 
Campath and the event of complex atrial arrhythmia. 
Print Time: 18-JUL-2014 02:07 PM If a field is blank, there is no data for that field Page 91 of 328 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information